<DOC>
	<DOCNO>NCT00051025</DOCNO>
	<brief_summary>The purpose study look safety effectiveness ONTAK previously treat patient NHL .</brief_summary>
	<brief_title>Phase II Study ONTAK Previously Treated Patients With Low-grade Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<criteria>Pathological diagnosis lowgrade ( indolent ) , Bcell , nonHodgkin 's lymphoma . Positive expression CD25 tumor cell lymph node biopsy define great 20 % malignant cell stain CD25 standardize immunohistochemical assay . Modified Ann Arbor Stage I , II , III IV . Patients must receive least two five prior therapy . One prior therapy must cytotoxic chemotherapy one prior therapy must monoclonal antibody therapy . Combination chemotherapy , include regimen use prior bone marrow transplantation , count single therapy purpose eligibility . Patients must bidimensionally measurable disease . Patients must 18 year age old . An ECOG performance status 0 , 1 , 2 . Acceptable organ function define follow : absolute neutrophil count ( ANC ) &gt; = 1,000/mm3 , platelet count &gt; = 50,000/mm3 , Hemoglobin &gt; = 8 g/dL ; Bilirubin &lt; = 1.5 time upper limit normal ( ULN ) ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; = 1.5 time upper limit normal ; Serum creatinine &lt; 1.8mg/dL ; Serum albumin &gt; = 3.0 g/dL . New York Heart Association classification I II history poorly control hypertension . Must free serious concurrent illness . Female patient must meet following criterion : If patient female childbearing potential , must negative serum beta human chorionic gonadotropin ( BhCG ) pregnancy test within seven day prior study entry must use effective mean contraception sexually abstinent least four week prior negative serum pregnancy test study entry . Female patient childbearing potential must agree practice effective method birth control entire treatment period least three week last treatment protocol . Patients cutaneous Tcell lymphoma . Patients previously treat ONTAK ( DAB389lL2 ) DAB486IL2 . Inability comply protocol requirement study . Pregnant woman lactate woman breast feed woman plan become pregnant treatment period three week last treatment protocol . Serious intercurrent medical illness active infection require parenteral antibiotic , would interfere ability patient carry treatment program . Seropositive human immunodeficiency virus ( HIV ) antibody . History ongoing Hepatitis B Hepatitis C infection . Another malignancy history another cancer less five diseasefree year ( resect basal squamous cell skin cancer situ cervical cancer ) . Patients know hypersensitivity ONTAK component : diphtheria toxin , interleukin2 , excipients . Any investigational agent within one month prior study entry . Prior radiation therapy within four week enrollment site evaluable disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>